Bluejay Diagnostics, Inc.

As of April 8, 2025, the market trend has shifted to mildly bearish, driven by bearish daily moving averages and weekly KST, despite mixed signals from the MACD and RSI across different time frames.

Bluejay Diagnostics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $2.44 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -187.61%.

As of Jun 18, Bluejay Diagnostics, Inc. has a market capitalization of 2.44 million, with net sales of 0.00 million and a net profit of -7.25 million over the last four quarters. The company reported shareholder's funds of 5.73 million and total assets of 6.66 million as of Dec 24.